Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Gynecologic 2Gastrointestinal 2

Conditions

Recurrence 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large B-Cell, Diffuse 2Pyloric Stenosis, Hypertrophic 1Lymphoma, Extranodal NK-T-Cell 1Advanced Solid Tumors 1

Interventions

Cyclophosphamide 100Rituximab 82fludarabine phosphate 46Peripheral Blood Stem Cell Transplantation 45fludarabine 43Lenalidomide 35Filgrastim 33Methotrexate 32Cytarabine 32Busulfan 32venetoclax 31Etoposide 31Cyclosporine 30Dexamethasone 29Radiotherapy 28Mycophenolic Acid 28Melphalan 28Bendamustine Hydrochloride 25Antilymphocyte Serum 25Vincristine 24Gemcitabine 24ibrutinib 22Whole-Body Irradiation 22Doxorubicin 20Tacrolimus 19Methylprednisolone 18Bortezomib 18Brentuximab Vedotin 16pembrolizumab 15Prednisone 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × apatinib × Lymphoid × Clear all
NCT04476459 2021-03-15

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

Sun Yat-sen University

Phase 1/2 Unknown
33 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT03376958 2019-07-25

Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma

Zhengzhou University

Phase 4 Completed
32 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡